Origin, Causative and New Approach of Vaccine Design of COVID-19 | ||
| Al- Anbar Medical Journal | ||
| Article 1, Volume 16, Issue 2, December 2020, Pages 25-27 PDF (243.33 K) | ||
| Document Type: Editorial article | ||
| DOI: 10.33091/amj.2020.170948 | ||
| Author | ||
| Mothana A. Khalil* | ||
| Department of Microbiology/Virology, College of Medicine, University of Anbar, Ramadi, Anbar, Iraq | ||
| Abstract | ||
| Coronavirus interactive disease 2019 (COVID-19) is a pandemic disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2(. It begins suddenly in December 2019 in Wuhan City, Hubei Province, China, then spread in 213 countries with 4,818,296 confirmed cases, of the 316,925 dead with 6.68% case fatality rate) until the nineteenth of May 2020). It is characterized by a mild common cold-like illness, to severe viral pneumonia leading to the acute respiratory distress syndrome that is potentially fatal | ||
| Keywords | ||
| OCV; Vaccine; COVID-19 | ||
| References | ||
|
[1] X.-W. Xu et al., “Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series,” bmj, vol. 368, 2020.
[2] X. Tang et al., “On the origin and continuing evolution of SARS-CoV-2,” Natl. Sci. Rev., 2020.
[3] A. C. Walls, Y.-J. Park, M. A. Tortorici, A. Wall, A. T. McGuire, and D. Veesler, “Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein,” Cell, 2020.
[4] C.-C. Lai, T.-P. Shih, W.-C. Ko, H.-J. Tang, and P.-R. Hsueh, “Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges,” Int. J. Antimicrob. Agents, p. 105924, 2020.
[5] J. F. W. Chan, S. K. P. Lau, K. K. W. To, V. C. C. Cheng, P. C. Y. Woo, and K.-Y. Yuen, “Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease,” Clin. Microbiol. Rev., vol. 28, no. 2, pp. 465–522, 2015.
[6] T. Zhang, Q. Wu, and Z. Zhang, “Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak,” Curr. Biol., 2020.
[7] K. G. Andersen, A. Rambaut, W. I. Lipkin, E. C. Holmes, and R. F. Garry, “The proximal origin of SARS-CoV-2,” Nat. Med., vol. 26, no. 4, pp. 450–452, 2020.
[8] Y.-R. Guo et al., “The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak–an update on the status,” Mil. Med. Res., vol. 7, no. 1, pp. 1–10, 2020.
[9] Y. A. Helmy, M. Fawzy, A. Elaswad, A. Sobieh, S. P. Kenney, and A. A. Shehata, “The COVID-19 Pandemic: A Comprehensive Review of Taxonomy, Genetics, Epidemiology, Diagnosis, Treatment, and Control,” J. Clin. Med., vol. 9, no. 4, p. 1225, 2020.
[10] V. K. Goyal and C. Sharma, “The novel coronavirus 2019: A naturally occurring disaster or a biological weapon against humanity: A critical review of tracing the origin of novel coronavirus 2019.”
[11] L. McNamara, “COVID-19—Fighting Fear and The Coronavirus Pandemic with Precautions and Quality Supplements.”
[12] T. Phan, “Genetic diversity and evolution of SARS-CoV-2,” Infect. Genet. Evol., vol. 81, p. 104260, 2020.
[13] P. Forster, L. Forster, C. Renfrew, and M. Forster, “Phylogenetic network analysis of SARS-CoV-2 genomes,” Proc. Natl. Acad. Sci., vol. 117, no. 17, pp. 9241–9243, 2020.
[14] S. F. Ahmed, A. A. Quadeer, and M. R. McKay, “Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies,” Viruses, vol. 12, no. 3, p. 254, 2020.
[15] T. T. Le et al., “The COVID-19 vaccine development landscape,” Nat Rev Drug Discov, vol. 19, pp. 305–306, 2020.
[16] S. Wu, “Progress and Concept for COVID‐19 Vaccine Development,” Biotechnol. J., p. 2000147, 2020.
[17] M. Uddin et al., “SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions,” Viruses, vol. 12, no. 5, p. 526, 2020.
[18] R. Lane, “Sarah Gilbert: carving a path towards a COVID-19 vaccine,” Lancet (London, England), vol. 395, no. 10232, p. 1247, 2020.
[19] Q. Gao et al., “Rapid development of an inactivated vaccine for SARS-CoV-2,” bioRxiv, 2020.
[20] D. Ricks, “Race for a Coronavirus Vaccine: Thanks in part to institutional support, CanSino Biologics, Moderna Therapeutics, and other developers are exploring diverse approaches against SARS-CoV-2,” Genet. Eng. Biotechnol. News, vol. 40, no. 5, pp. 16–18, 2020.
[21] N. Zhang et al., “Current development of COVID-19 diagnostics, vaccines and therapeutics,” Microbes Infect., 2020.
[22] A. Sarkar and U. Maulik, “Vaccines and Treatment Strategies for SARS-COV-2,” 2020.
[23] W.-H. Chen, U. Strych, P. J. Hotez, and M. E. Bottazzi, “The SARS-CoV-2 vaccine pipeline: an overview,” Curr. Trop. Med. reports, pp. 1–4, 2020. | ||
|
Statistics Article View: 131 PDF Download: 103 |
||